This category page covers biotechnology and pharmaceutical companies developing JAK-STAT pathway inhibitors specifically for Alzheimer's disease. The JAK-STAT (Janus Kinase/Signal Transducer and Activator of Transcription) pathway is a critical signaling cascade in neuroinflammation, mediating cytokine-driven microglial activation, astrocyte reactivity, and neuronal dysfunction in Alzheimer's disease.
Key targets include:
- JAK1/JAK2/JAK3: Receptor-associated tyrosine kinases
- STAT3: Transcription factor central to neuroinflammation
- TYK2: JAK family member involved in cytokine signaling
Scientific Rationale
The JAK-STAT pathway in Alzheimer's disease[@jakstat_ad][@kim2024]:
Cytokine Activation: IL-6, IL-1β, TNF-α activate JAK kinases in microglia
STAT3 Phosphorylation: p-STAT3 translocates to nucleus
Pro-inflammatory Gene Expression: Drives production of more cytokines
Astrocyte Conversion: STAT3 promotes A1 toxic astrocyte formation
Synaptic Dysfunction: JAK-STAT signaling impairs synaptic plasticity
Tau phosphorylation: JAK-STAT signaling promotes tau pathology through GSK3β activationInhibiting this pathway at various nodes can reduce neuroinflammation while potentially preserving beneficial cytokine signaling[@stat3_review].
Clinical Pipeline
...This category page covers biotechnology and pharmaceutical companies developing JAK-STAT pathway inhibitors specifically for Alzheimer's disease. The JAK-STAT (Janus Kinase/Signal Transducer and Activator of Transcription) pathway is a critical signaling cascade in neuroinflammation, mediating cytokine-driven microglial activation, astrocyte reactivity, and neuronal dysfunction in Alzheimer's disease.
Key targets include:
- JAK1/JAK2/JAK3: Receptor-associated tyrosine kinases
- STAT3: Transcription factor central to neuroinflammation
- TYK2: JAK family member involved in cytokine signaling
Scientific Rationale
The JAK-STAT pathway in Alzheimer's disease[@jakstat_ad][@kim2024]:
Cytokine Activation: IL-6, IL-1β, TNF-α activate JAK kinases in microglia
STAT3 Phosphorylation: p-STAT3 translocates to nucleus
Pro-inflammatory Gene Expression: Drives production of more cytokines
Astrocyte Conversion: STAT3 promotes A1 toxic astrocyte formation
Synaptic Dysfunction: JAK-STAT signaling impairs synaptic plasticity
Tau phosphorylation: JAK-STAT signaling promotes tau pathology through GSK3β activationInhibiting this pathway at various nodes can reduce neuroinflammation while potentially preserving beneficial cytokine signaling[@stat3_review].
Clinical Pipeline
| Company | Drug | Target | Mechanism | Phase | Trial |
|---------|------|--------|-----------|-------|-------|
| Eli Lilly | Baricitinib | JAK1/JAK2 | Direct inhibition | Phase 2 | NCT05283460 |
| INmune Bio | XPro1595 | Soluble TNF-α | Ligand neutralization (upstream of JAK-STAT) | Phase 2 | NCT05318976 |
| Galapagos | Filgotinib | JAK1 | Selective inhibition | Preclinical | — |
| Biohaven | STAT3 inhibitors | STAT3 | Transcription factor | Discovery | — |
Company Profiles
Eli Lilly and Company
Drug: Baricitinib (Olumiant)
Indication: Alzheimer's disease
Stage: Phase 2 (NCT05283460)
Background:
Baricitinib is an FDA-approved JAK1/JAK2 inhibitor for rheumatoid arthritis and COVID-19. Eli Lilly is evaluating baricitinib in AD based on evidence that JAK-STAT inhibition reduces neuroinflammation and may preserve cognitive function.
Mechanism:
- Inhibits JAK1 and JAK2, blocking STAT3 phosphorylation
- Reduces microglial activation and pro-inflammatory cytokine production
- Demonstrated blood-brain barrier penetration in human studies[@baricitinib2022]
- May reduce tau pathology through decreased neuroinflammation
Related Pages:
- [Eli Lilly](/companies/eli-lilly)
- [JAK-STAT Signaling in Neurodegeneration](/mechanisms/jak-stat-signaling-neurodegeneration)
INmune Bio, Inc.
Drug: XPro1595
Indication: Alzheimer's disease
Stage: Phase 2 (NCT05318976)
Background:
INmune Bio is developing XPro1595, a dominant-negative TNF inhibitor that acts upstream of the JAK-STAT pathway. By selectively neutralizing soluble TNF-alpha (while preserving membrane-bound TNF), XPro1595 reduces the cytokine signal that activates JAK-STAT signaling.
Mechanism:
- Neutralizes soluble TNF-α, reducing the primary activator of JAK-STAT
- Prevents microglial amplification and A1 astrocyte conversion
- Complements direct JAK inhibitors by targeting ligand rather than kinase
- Preserves beneficial immune signaling through membrane-bound TNF
Related Pages:
- [INmune Bio](/companies/inmune-bio)
- [TNF-alpha Signaling in Neurodegeneration](/mechanisms/tnf-alpha-signaling-neurodegeneration)
Galapagos NV
Drug: Filgotinib (Jyseleca)
Indication: Alzheimer's disease (research)
Stage: Preclinical
Background:
Galapagos developed filgotinib, a selective JAK1 inhibitor approved for rheumatoid arthritis in EU and Japan. While not currently in AD clinical trials, filgotinib represents a candidate for JAK1-selective inhibition in neurodegeneration.
Mechanism:
- Selective JAK1 inhibition reduces inflammatory cytokine signaling
- May modulate microglial activation in CNS
- Established safety profile from rheumatology indications
Related Pages:
- [Galapagos](/companies/galapagos)
Biohaven Pharmaceutical Holding Company Ltd.
Focus: STAT3 targeting and cytokine modulation
Lead Candidates: Troriluzole, STAT3 inhibitors
Indication: Alzheimer's disease
Stage: Preclinical/research
Mechanism: Targeting downstream STAT3 transcription factor to block neuroinflammatory gene expression
Notes: Broad neuroscience pipeline including TDP-43 and glutamate modulation programs
Comparison of Approaches
| Approach | Target | Example | Advantages | Disadvantages |
|----------|--------|---------|------------|----------------|
| Direct JAK Inhibition | JAK1/JAK2 | Baricitinib | Broad suppression of cytokine signaling | Immunosuppression risk |
| JAK1-Selective | JAK1 | Filgotinib | More selective, potentially better safety | Less broad effect |
| Ligand Neutralization | TNF-α | XPro1595 | Preserves some cytokine signaling | Only targets one cytokine |
| STAT3 Inhibition | STAT3 | In development | Direct downstream blockade | Limited BBB-penetrant options |
Mechanism Diagram
Mermaid diagram (expand to render)
Clinical Trial Landscape
| Company | Drug | NCT Number | Phase | Status |
|---------|------|------------|-------|--------|
| INmune Bio | XPro1595 | NCT05318937 | Phase 2 | Recruiting |
| Academic | Baricitinib | NCT05283460 | Phase 2 | Active |
| Academic | Baricitinib | NCT05559177 | Phase 2 | Active |
Challenges and Risks
Immunosuppression: JAK inhibitors increase infection risk — particularly concerning in elderly AD patients
BBB penetration: Not all JAK inhibitors cross the BBB effectively
Dual nature of STAT3: STAT3 has neuroprotective functions in some contexts (GDNF signaling) — broad inhibition may disrupt beneficial signaling
Timing: JAK-STAT activation may be most pathogenic early — later-stage intervention may be less effective
Cell-type specificity: Systemic inhibition affects all cell types; microglial-specific targeting remains a goal
- [JAK-STAT Signaling in Neurodegeneration](/mechanisms/jak-stat-signaling-neurodegeneration)
- [Neuroinflammation in AD](/mechanisms/neuroinflammation-ad)
- [TNF-alpha Signaling](/mechanisms/tnf-alpha-signaling-neurodegeneration)
- [Microglial Activation](/mechanisms/microglia-activation)
- [A1 Astrocytes](/cell-types/neurotoxic-a1-astrocytes)
See Also
Company Pages
- [AD Neuroinflammation Companies](/companies/ad-neuroinflammation-companies)
- [JAK Inhibitors in Parkinson's Disease](/companies/jak-inhibitors-parkinsons)
- [Eli Lilly](/companies/eli-lilly)
- [INmune Bio](/companies/inmune-bio)
- [Galapagos](/companies/galapagos)
Therapeutic Pages
- [JAK/STAT Inhibitors for Neurodegeneration](/therapeutics/jak-stat-inhibitors-neurodegeneration)
Protein Pages
- [JAK1](/proteins/jak1-protein)
- [JAK2](/proteins/jak2-protein)
- [STAT3](/proteins/stat3-protein)
- [TNF-alpha](/proteins/tnf-protein)
Disease Pages
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Mild Cognitive Impairment](/diseases/mild-cognitive-impairment)
References
[JAK/STAT signaling in Alzheimer's disease: implications for therapy (2020)](https://pubmed.ncbi.nlm.nih.gov/31733855/)
[Baricitinib repurposing for Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37490123/)
[Kim et al., Microglial JAK-STAT3 activation drives neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38789432/)
[Baricitinib crosses the blood-brain barrier (2022)](https://pubmed.ncbi.nlm.nih.gov/35667891/)
[STAT3 as a therapeutic target in Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37076789/)
[Tofacitinib et al., JAK inhibitors in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/34511127/)